| Literature DB >> 30487643 |
Kohei Hamanaka1, Yuji Sugawara2, Takeyoshi Shimoji3, Tone Irene Nordtveit4, Mitsuhiro Kato5, Mitsuko Nakashima6, Hirotomo Saitsu6, Toshimitsu Suzuki7, Kazuhiro Yamakawa7, Ingvild Aukrust4, Gunnar Houge4, Satomi Mitsuhashi1, Atsushi Takata1, Kazuhiro Iwama1, Ahmed Alkanaq1, Atsushi Fujita1, Eri Imagawa1, Takeshi Mizuguchi1, Noriko Miyake1, Satoko Miyatake1,8, Naomichi Matsumoto9.
Abstract
Potocki-Shaffer syndrome (PSS) is a contiguous gene syndrome caused by 11p11.2 deletions. PSS is clinically characterized by intellectual disability, craniofacial anomalies, enlarged parietal foramina, and multiple exostoses. PSS occasionally shows autism spectrum disorder, epilepsy, and overgrowth. Some of the clinical features are thought to be associated with haploinsufficiency of two genes in the 11p11.2 region; variants affecting the function of ALX4 cause enlarged parietal foramina and EXT2 lead to multiple exostoses. However, the remaining clinical features were still yet to be linked to specific genetic alterations. In this study, we identified de novo truncating variants in an 11p11.2 gene, PHF21A, in three cases with intellectual disability and craniofacial anomalies. Among these three cases, autism spectrum disorder was recognized in one case, epilepsy in one case, and overgrowth in two cases. This study shows that PHF21A haploinsufficiency results in intellectual disability and craniofacial anomalies and possibly contributes to susceptibility to autism spectrum disorder, epilepsy, and overgrowth, all of which are PSS features.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30487643 PMCID: PMC6460561 DOI: 10.1038/s41431-018-0289-x
Source DB: PubMed Journal: Eur J Hum Genet ISSN: 1018-4813 Impact factor: 4.246